Ardelyx Inc ARDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ARDX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $7.57
- Day Range
- $5.07–6.47
- 52-Week Range
- $3.16–10.13
- Bid/Ask
- $5.44 / $5.51
- Market Cap
- $1.24 Bil
- Volume/Avg
- 219,278 / 5.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.49
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 267
- Website
- https://www.ardelyx.com
Comparables
Valuation
|
Metric
|
ARDX
|
MORF
|
VERV
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 8.19 | 2.36 | 0.72 |
Price/Sales | 7.49 | — | 21.66 |
Price/Cash Flow | — | — | — |
Price/Earnings
ARDX
MORF
VERV
Financial Strength
|
Metric
|
ARDX
|
MORF
|
VERV
|
|---|---|---|---|
Quick Ratio | 4.06 | 37.20 | 19.56 |
Current Ratio | 4.53 | 38.17 | 19.82 |
Interest Coverage | −4.96 | — | — |
Quick Ratio
ARDX
MORF
VERV
Profitability
|
Metric
|
ARDX
|
MORF
|
VERV
|
|---|---|---|---|
Return on Assets (Normalized) | −18.93% | −18.85% | −25.18% |
Return on Equity (Normalized) | −33.93% | −19.43% | −31.95% |
Return on Invested Capital (Normalized) | −20.90% | −23.26% | −31.26% |
Return on Assets
ARDX
MORF
VERV
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Pwjnbsvlm | Rtvs | $636.9 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wndkyyjm | Nbffnj | $122.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vqnpnwkb | Hqnvzbj | $115.1 Bil | |||
| Moderna Inc
MRNA
| Bynxwblc | Rnlm | $44.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xfwwrpb | Fftkxmr | $31.3 Bil | |||
| argenx SE ADR
ARGX
| Xjwlgwnfk | Hpw | $26.2 Bil | |||
| BioNTech SE ADR
BNTX
| Zqcjbzjnx | Vsyq | $19.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bvnkdpjbn | Rbykrm | $15.6 Bil | |||
| United Therapeutics Corp
UTHR
| Jjyllvqwh | Xgzr | $14.1 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Rrhthgmnt | Cqrhww | $11.7 Bil |